आईएसएसएन: 2381-8727

सूजन, कैंसर और एकीकृत थेरेपी के अंतर्राष्ट्रीय जर्नल

खुला एक्सेस

हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।

ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं

में अनुक्रमित
  • शैक्षणिक कुंजी
  • RefSeek
  • हमदर्द विश्वविद्यालय
  • पबलोन्स
  • यूरो पब
  • आईसीएमजेई
इस पृष्ठ को साझा करें


A Digital Patient-Input Tool that Combines Family Cancer History Screening and Newly Diagnosed Diabetes can be Used to Identify Those Who are at High Risk for Developing Pancreatic Cancer

Clatte F

The ability to enroll in pancreatic surveillance programs would be made possible by the collection of family history information, which could be a useful tool for identifying individuals who are more likely to develop pancreatic cancer. Weight loss and newly diagnosed diabetes may also be used as an early indicator of pancreatic cancer [1]. Combining family history and the Enriching New-Onset Diabetes for Pancreatic Cancer (ENDPAC) model to identify people who  might benefit from pancreatic surveillance is the focus of this study. The ENDPAC model's criteria were combined with questions about family cancer history in a novel questionnaire and digital input tool. The high-risk pancreatic clinic enrolled individuals who met the ENDPAC criteria directly [2 ]. A genetic counselor was recommended to those who met the criteria for a significant family history of cancer. 453 patients completed the questionnaire. 25.8% (117/453) of those had significant risk factors in their families [3]. Five of the 18 people (15.4%) who had previously undergone genetic testing had a pathogenic variant. Out of 117 people who were identified by the questionnaire as having a
significant family history, 34 (29.9%) underwent genetic testing. A pathogenic variant was present in four (11.8 percent) of these patients. Furthermore, through overflow family testing, two kin were found to convey pathogenic variations. From the 453 patients, four (0.9 percent) met the ENDPAC criteria. Two of them had pancreatic cancer, and the other two had signed up for the surveillance program. In conclusion, the ENDPAC model and family history screening can be combined to identify people at high risk for pancreatic cancer and make it easier to refer them to genetic counseling
and high-risk clinics [4 ].